ライフサイエンスコーパス: second cancer

1 onsequences (accelerated atherosclerosis and second cancer).

2 p is associated with a substantive risk of a second cancer.

3 kely includes recurrences misclassified as a second cancer.

4 k of death as a result of cardiac disease or second cancer.

5 ment of de novo leukaemia or therapy-related second cancers.

6 Two of the 86 (2.3%) patients developed second cancers.

7 We have therefore examined the incidence of second cancers.

8 ociated with an increased risk of developing second cancers.

9 nd reduction in numbers of germline mutation second cancers.

10 has been accompanied by an increased risk of second cancers.

11 ure to TKIs increases the risk of developing second cancers.

12 milar risks of circulatory complications and second cancers.

13 er, substantially increase the risk of later second cancers.

14 s and a predisposition to the development of second cancers.

15 (HR, 0.90; 95% CI, 0.61 to 1.32) followed by second cancers (13.6% of deaths; HR, 1.24; 95% CI, 0.49

16 mportant, including the risk of developing a second cancer after radiotherapy.

17 We compared the risk of a second cancer among these patients with the risk that wa

18 This study quantified the risk of second cancers among 16 367 patients with CLL in the pop

19 Understanding risk factors for second cancers among cancer survivors is crucial.

20 ave more than twice the risk of developing a second cancer and an increased frequency of certain canc

21 a on HL relapse, late recurrence, and excess second cancer and cardiac late-effects mortality were es

22 significantly associated with mortality from second cancers and other causes, whereas menopausal horm

23 The 15-year cumulative risks of all second cancers and secondary ANLL were 37% and 17%, resp

24 re at high risk of potentially life-limiting second cancers and treatment-associated cardiovascular d

25 onger and are at risk for cancer recurrence, second cancers, and complications from treatment.

26 sis and pinealoblastoma, minimizes long-term second cancers, and has few systemic and no ocular toxic

27 zoxane may reduce treatment efficacy, induce second cancers, and thus compromise overall survival amo

28 A relatively small proportion of second cancers are related to radiotherapy in adults, su

29 he first cancer sites the RR of developing a second cancer associated with radiotherapy exceeded 1, a

30 fied either the p.His1047Leu alteration or a second cancer-associated alteration, p.His1047Arg, in ni

31 Cumulative incidence (+/-SE) of a second cancer at 50 years after diagnosis was 51.0% (+/-

32 Twenty-six patients developed a second cancer at least 6 months after the HCL diagnosis

33 experience significantly increased risks of second cancers at various sites for 2 to 3 decades.

34 We aimed to estimate the proportion of second cancers attributable to radiotherapy in adults wi

35 also common after HCT, including infections, second cancers, bone loss, and cardiovascular, pulmonary

36 ation, was associated with more toxicity and second cancers but a significantly longer time to diseas

37 complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear.

38 increased risk of early mortality related to second cancers, cardiac disease, and infection.

39 as a significant excess risk of all types of second cancers combined (SIR, 3.40; 95% CI, 1.55-6.45),

40 survivors had a higher risk of developing a second cancer compared with an age- and sex-matched gene

41 had an increased probability of developing a second cancer compared with the general population.

42 to risk estimates consistent with high-dose second-cancer data.

43 or cancer induction at high doses and recent second-cancer data.

44 identify the cell cycle-regulated genes in a second cancer-derived cell line and provide a comprehens

45 eservoir from which proliferative lesions or second cancers develop once additional genetic abnormali

46 ival, hematologic toxicity, ocular toxicity, second cancer development and electroretinogram response

47 All second cancers diagnosed in patients included in the TME

48 f the following events: CBC diagnosis, other second cancer diagnosis, death, last tumor registry foll

49 as well as the mutually increased risks for second cancer for both organs, grain fiber and whole gra

50 There is a substantial risk of a second cancer for persons with hereditary retinoblastoma

51 Moreover, modeling second cancers gives unique insights into human carcinog

52 due to longer patient survival times, these second cancers have become of increasing concern.

53 nly orchiectomy, had an increased risk for a second cancer (hazard ratio [HR], 3.2; 95% CI, 1.9 to 5.

54 rly follow-up forms recorded any recurrence, second cancer, hospital admission, or death.

55 HCL, there was an increase in the number of second cancers; however, it did not reach statistical si

56 ed the long-term probability of developing a second cancer in a large pooled cohort of patients treat

57 incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardi

58 Results Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (9

59 n chronic inflammation, atherosclerosis, and second cancer in MPNs favors early intervention at the t

60 Relative risks (RRs) for second cancer in patients treated with radiotherapy vers

61 ture atherosclerosis," clonal evolution, and second cancer in patients with MPNs.

62 e that OC or PMH use increases the risk of a second cancer in the contralateral breast.

63 8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5%

64 definitively assess their risk of developing second cancers in a lifetime.

65 ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-s

66 tion is used in cancer therapy it can induce second cancers in nearby organs.

67 what extent these strategies reduce risk of second cancers in such patients.

68 a high incidence of apparently metachronous second cancers in the first 2 years after resection.

69 However, recent studies of radiation-induced second cancers in the lung and breast, covering a very w

70 m diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), me

71 derstand the contribution of radiotherapy to second cancer induction and pursue well-coordinated effo

72 Estimating the risk of solid second cancers involves modeling: because of long latenc

73 Second cancer is the leading cause of death in long-term

74 may be less frequent long-term effects (eg, second cancers, lymphedema, osteoporosis).

75 Comorbidities, severe adverse events, second cancers, management of relapse and death as a res

76 or other interventions to reduce the rate of second cancers may be valuable.

77 on the different causes of death, including second cancer mortality, noncancer mortality, and cause-

78 cause many acute and late complications (eg, second cancers, neurocognitive deficits, endocrine disor

79 The number of second cancers observed was compared with the number exp

80 Two thousand one hundred fifty-three second cancers (observed-to-expected ratio [O/E] = 2.3;

81 Second cancers occur in a small percentage of patients r

82 Overall, 1,296 second cancers occurred against 1,014 expected [observed

83 ages (10 to 16 years), the largest number of second cancers occurred in the digestive tract (O/E = 19

84 nitially with low-dose TBI was monitored for second cancer occurrence.

85 SIRs for second cancers of the colon, soft tissue, melanoma, and

86 age points in suitable women but can cause a second cancer or heart disease decades later.

87 rial and investigated whether they developed second cancers or had histologic residual disease.

88 Interventions to prevent second cancers, particularly PCM, may offer substantial

89 sing data from the American Cancer Society's second Cancer Prevention Study (CPS II), a cohort study

90 No differences were found in second cancer probability between patients who were trea

91 The second cancer profiles among cervical SCC and AC survivo

92 The awareness of an increased risk of second cancer remains crucial for survivors of Hodgkin's

93 n the late 1980s, on the long-term risk of a second cancer remains unknown.

94 Data on smoking and second cancer risk among cancer survivors are limited.

95 king before first cancer diagnosis increases second cancer risk among cancer survivors, and elevated

96 Factors contributing to second cancer risk include the carcinogenic effects of i

97 Second cancer risk peaked 5 to 9 years after chemotherap

98 Second cancer risk was high during all follow-up interva

99 or differences translate into differences in second cancer risk.

100 We sought to quantify the second cancer risks and to investigate the impact of fam

101 Second cancer risks for patients who received chemothera

102 d susceptibility, may contribute to elevated second cancer risks in colorectal cancer survivors compa

103 creasing concern regarding radiation-related second-cancer risks in long-term radiotherapy survivors

104 CI, 1.29 to 1.34) and AC survivors (n = 920 second cancers; SIR, 1.29; 95% CI, 1.22 to 1.38).

105 mong both cervical SCC survivors (n = 10,559 second cancers; SIR, 1.31; 95% CI, 1.29 to 1.34) and AC

106 n, can be important at the doses relevant to second cancer situations.

107 Failures are due to relapse, toxicity, and second cancers such as therapy-related myeloid leukemia

108 Germline mutations of a second cancer susceptibility gene BRCA1, are associated

109 BT had no higher probability of developing a second cancer than patients who were treated with surger

110 complex (MHC) loci, confirming that it is a second cancer that can be transmitted between devils as

111 o in the burden of "late effects," including second cancers, that compromise quality of life and limi

112 late relapse of disease, the development of second cancers, the effect of the disease and treatment

113 ge 0 are at increased risk of infections and second cancers, the risk of progression requiring treatm

114 eath has been from HD: five patients died of second cancers, two of cardiac disease, and one of alcoh

115 The RR of developing a second cancer was 15.4 (95% confidence interval [CI], 10

116 in the RT group the actuarial frequency of a second cancer was 16% at 20 years.

117 The risk of a second cancer was 2.2 times higher than the expected ris

118 The standardized incidence ratio for any second cancer was 2.98 (95% CI, 2.82 to 3.14).

119 The risk of a second cancer was assessed by calculating the standard i

120 The risk of second cancer was lower than expected (observed-to-expec

121 Relative risk (RR) of second cancer was raised after chemotherapy alone (RR, 2

122 The risk of all second cancers was 1.3-fold higher for HL survivors with

123 The number of second cancers was compared with the number expected fro

124 ned by histology analysis and development of second cancers was documented.

125 r Registry, the SIR for risk of all types of second cancers was similar to that in SEER 9 (SIR, 3.45;

126 With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting

127 Significantly increased risks of second cancers were observed in all HD age groups.

128 No second cancers were observed in the CMT group; in the RT

129 Similar numbers of cardiac events and second cancers were recorded in the groups.

130 Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients tr